Cvs Pharmacy
NDC 59779-276
Product Information
Cvs Pharmacy is a ANDA-approved product labeled by Cvs Pharmacy. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a yellow product. This product entry covers the primary NDC 59779-276 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 59779-276?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CETIRIZINE HYDROCHLORIDE (UNII: 64O047KTOA)
- CETIRIZINE (UNII: YO7261ME24) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ACETIC ACID (UNII: Q40Q9N063P)
- GLYCERIN (UNII: PDC6A3C0OX)
- METHYLPARABEN (UNII: A2I8C7HI9T)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- PROPYLPARABEN (UNII: Z8IX2SC1OH)
- WATER (UNII: 059QF0KO0R)
- SUCRALOSE (UNII: 96K6UQ3ZD4)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1014673 - cetirizine HCl 5 MG in 5 mL Oral Solution
- RxCUI: 1014673 - cetirizine hydrochloride 1 MG/ML Oral Solution
- RxCUI: 1014673 - cetirizine HCl 1 MG/ML Oral Syrup
- RxCUI: 1014673 - cetirizine HCl 5 MG per 5 ML Oral Solution
* Please review the full disclaimer at the bottom of this page.
Patient Education
Cetirizine Injection
Cetirizine injection is used to treat acute urticaria in adults and children 6 months of age or older. Cetirizine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms.
[Learn More]
* Please review the full disclaimer at the bottom of this page.